Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07491718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Study acronym: TAKO MEMRI
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Interventions: Bisoprolol (Drug), Dapagliflozin (10mg Tab) (Drug), No medications (Drug), Valsartan (Drug), sacubitril/ valsartan (Drug) to Bisoprolol (Drug), Dapagliflozin (10mg Tab) (Drug), No medications (Drug), Valsartan (Drug), sacubitril/ valsartan (Drug) Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 1 of 5 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.
Trial Details
NCT Number NCT07491718
Lead Sponsor University of Edinburgh
Conditions Takotsubo Cardiomyopathy
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov